Abstract-Mutations in the bone morphogenetic protein (BMP) receptor-2 (BMPR2) have been found in patients with idiopathic pulmonary arterial hypertension (IPAH); however, the mechanistic link between loss of BMPR2 signaling and the development of pulmonary arterial hypertension is unclear. We hypothesized that, contrary to smooth muscle cells, this pathway promotes survival in pulmonary artery endothelial cells (ECs) and loss of BMPR2 signaling will predispose to EC apoptosis. ECs were treated with BMP-2 or BMP-7 (200 ng/mL) for 24 hours in regular or serum-free (SF) medium, with and without addition of tumor necrosis factor ␣, and apoptosis was assessed by flow cytometry (Annexin V), TUNEL, or caspase-3 activity. Treatment for 24 hours in SF medium increased apoptosis, and both BMP-2 and BMP-7 significantly reduced apoptosis in response to serum deprivation to levels not different from serum controls. Transfection with 5 g of small interfering RNAs for BMPR2 produced specific gene silencing assessed by RT-PCR and Western blot analysis. BMPR2 gene silencing increased apoptosis almost 3-fold (Pϭ0.0027), even in the presence of serum. Circulating endothelial progenitor cells (EPCs) isolated from normal subjects or patients with IPAH were differentiated in culture for 7 days and apoptosis was determined in the presence and absence of BMPs. BMP-2 reduced apoptosis induced by serum withdrawal in EPCs from normal subjects but not in EPCs isolated from patients with IPAH. These results support the hypothesis that loss-of-function mutations in BMPR2 could lead to increased pulmonary EC apoptosis, representing a possible initiating mechanism in the pathogenesis of pulmonary arterial hypertension. 
I
diopathic pulmonary arterial hypertension (IPAH) is a rare and fatal disorder, with an estimated incidence of 1 to 2 per million cases per year 1 and a median survival from diagnosis of only 2.8 years. Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance (PVR) caused by vasoconstriction and excessive remodeling of small pulmonary arteries, resulting in widespread microvascular narrowing and obliteration. 1 Clinically, the pulmonary pathology in advanced PAH is characterized by abnormal muscularization of pulmonary arterioles, intimal thickening, and fibrosis, 2 as well as the presence of plexiform lesions, 3 which are believed to result from dysregulation of endothelial cell (EC) growth. 3 Although increased EC growth may be a feature of late stages of disease, there is increasing evidence that other mechanisms may predominate in early phases of PAH. In experimental models, blockade of EC growth factor receptors resulted in the potentiation of PAH and marked worsening the pathological vascular remodeling, even reproducing some of the "angioproliferative" features typical of advanced PAH. 4 Interestingly, this effect could be reversed by inhibitors of apoptosis, 4 suggesting that increased apoptosis of ECs in response to loss of survival signaling created conditions favoring the emergence of apoptosis-resistant cells with increased growth potential. Moreover, we have shown that overexpression of EC growth and survival factors, such as vascular endothelial growth factor (VEGF) and angiopoietin-1, prevented the development of monocrotalineinduced PAH, 5, 6 an effect that was associated with reduced EC apoptosis. Together, the findings implicate EC apoptosis as a central mechanism in the initiation of PAH and suggest that pulmonary microvascular endothelium is dependent on tonic survival signaling, possibly more so than for other circulations.
The most significant advance in the understanding the pathogenesis of PAH has been the recent demonstration of germline mutations in the familial form of this disease that have been mapped to a single locus on chromosome 2q31-32. 7 Mutations in the open reading frame of the bone morphogenetic protein (BMP) receptor-2 (BMPR2) gene were identified in Ϸ40% of familial PAH and in up to Ϸ15% of patients with no family history (ie, IPAH). 8 -11 BMPR2 is a member of the transforming growth factor (TGF)-␤ superfamily of transmembrane serine/threonine kinase receptors. More than 46 different mutations of BMPR2 have already been identified, some of which have been demonstrated to cause loss of the receptor function. However, how haploinsufficiency in this BMPR2 leads to pulmonary hypertension is unknown.
The ligands for the BMPR2 receptor represent a family of secreted growth factors known as the BMPs. Signal transduction through this pathway involves heterodimerization of BMPR2 with BMPR1, which results in phosphorylation of BMPR1, initiating activation of signal transduction. BMPs can have pleiotropic effects depending on the cell type, the specific ligand, and the environmental context. [12] [13] [14] For example, BMPs can inhibit proliferation and induce apoptosis in human pulmonary artery smooth muscle cells 15, 16 ; however, in other cell types, including cardiomyocytes and epithelial cells, signaling via this pathway can have an opposite effect and promote cell survival. 17, 18 Therefore, the role of BMPR2 in the normal lung may be complex, with different biological actions on different vascular cells, and its effect, particularly on pulmonary ECs and endothelial progenitor cells (EPCs) from patients with IPAH, has yet to be clarified.
The aim of the present study was to elucidate the effect of BMPR2 signaling on survival of pulmonary arterial ECs and EPCs isolated from normal subjects or patients with IPAH. We now show for the first time that BMP-2 and BMP-7 promoted survival of human pulmonary arterial ECs as well as EPCs isolated from normal subjects, consistent with a role of the BMPR2 signaling pathway in protecting pulmonary microvascular EC from apoptosis. In contrast, in EPCs isolated from IPAH patients, there was either reduced survival or even an accentuation in apoptosis in response to BMPs. These results suggest a new paradigm for loss-offunction BMPR2 mutations in the pathogenesis of PAH, contributing to the initial endothelial microvascular loss, as well as potentiating reactive arterial remodeling in the remaining arteriolar and arterial bed.
Materials and Methods

Cell Culture and Experimental Design
Human pulmonary artery ECs (HPAECs) were obtained from (Cambrex) and grown in EBM-2 (SingleQuot Media BulletKit, Cambrex) supplemented with 2% fetal bovine serum. All experiments were performed using subconfluent cultures (Ϸ80%), of the same batch, derived from pooled donors, and used only between passages 3 to 4. Culture conditions for other cell types are described in the online data supplement available at http://circres.ahajournals.org. To induce apoptosis, cells were exposed to tumor necrosis factor (TNF)-␣ (20 ng/mL; R&D) or serum withdrawal for 24 hours in the presence or absence of BMP-2 or BMP-7 (200 ng/mL; R&D). Cells were pretreated with BMPs for 2 hours before exposure to TNF. After treatment, cells were either suspended for flow cytomet- ric analysis, fixed and stained (TUNEL) for microscopic analysis, or lysed for caspase-3 activity assays.
Apoptosis Assays
Apoptosis was assessed by 3 independent methods.
Flow Cytometry
Apoptotic and necrotic cell death was assessed in HPAECs by flow cytometric analysis (Annexin V-FLUOS Staining Kit, Roche) under control or apoptosis-inducing conditions, in the presence or absence of BMPs. At the end of the treatment period, cells were suspended by a brief trypsinization (0.05% with EDTA) and washed twice with cold PBS. Cells were then resuspended in 100 L of 1ϫ binding buffer with 2 L of Annexin V-fluorescein isothiocyanate (FITC) and 2 L of propidium iodide (PI). The cells were gently mixed and incubated for 15 minutes at room temperature in the dark, and then 400 L of 1ϫ binding buffer was added to each tube before analysis. Fluorescence was induced with the 488-nm argon laser and monitored at 512 nm (FL1) and 543 nm (FL3) on a Beckman Coulter Cytomics FC500 analyzer.
TUNEL Staining
After the various treatments, cells were fixed in 2% paraformaldehyde in PBS for 10 minutes and washed 3 times with PBS, permeabilized with 0.2% Triton-X, and stained using the Dead/End Fluorometric apoptosis detection system (Promega), following the instructions of the manufacturer, producing fluorescein TUNEL staining and PI nuclear counterstaining. Merged images were generated by dual scanning at 488 nm and 543 nm with a confocal microscope (Bio-Rad, Radiance 2100) and TUNEL-positive or -negative cells were counted in 6 random fields per well in a blinded fashion.
Caspase-3 Activity
A fluorometric assay kit (Promega) was used for detection of activated caspase-3. Freeze/thaw cytosolic extracts were incubated at 30°C with the fluorgenic substrate, 7-amino-4methyl coumarin (Ac-DEVD-AMC) in 96-well microliter plates, and emission fluorescence was detected at 460 nm after excitation at 360 nm. Results were calculated from a standard curve per the instructions of the manufacturer. Activated caspase-3 was also assessed by Western analysis as described in the online data supplement.
Silencing of BMPR2 mRNA
Gene silencing of BMPR2 was achieved using small interfering RNA (siRNA) as described by Elbashir and colleagues 19, 20 (see online data supplement). Forty-eight to 72 hours after transfection, HPAECs were lysed with 100 L of sodium dodecyl sulfate (SDS) sample buffer (10 mmol/L Tris-HCl, pH 6.8, 4% SDS, 20% glycerol, 0.4% dithiothreitol, 1 mmol/L orthovanadate), and BMPR2 expression was assessed by semiquantitative RT-PCR and Western blot analysis, as described in the online data supplement. 
Isolation and Differentiation of EPCs
All use of human material was approved by the Research Ethics Boards at St. Michael's Hospital and the University Health Network. EPCs were isolated from peripheral blood as described previously. 21 Briefly, peripheral venous blood was obtained from 16 patients with IPAH recruited from the Pulmonary Hypertension clinic (age 45Ϯ13 years, 15 women; see Table) or 5 normal subjects (age 38Ϯ11 years, 4 women) after written informed consent. The mononuclear cell fraction was isolated by Ficoll-Paque density gradient (Becton Dickinson) centrifugation and washed 3 times with PBS, and cells were plated at a density of 1.5ϫ10 6 mononuclear cells/mL on fibronectin-coated culture slides (Becton Dickinson) in basal medium-2 (EBM-2; Cambrex) supplemented with 5% FBS, with human VEGF-A, fibroblast growth factor-2, epidermal growth factor, insulin-like growth factor-1, and ascorbic acid (EGM-2 MV SingleQuot Media BulletKit; Cambrex). Cells were grown for 7 days with culture media changes every 48 hours and then characterized as described in the online data supplement. EPCs were treated with BMP-2 (200 ng/mL) for 24 hours in EGM-2 medium in the presence or absence of 5% FBS, and the number of cells undergoing apoptosis was determined by flow cytometry.
Statistical Analysis
Data are presented as meanϮSEM. Significance of differences was assessed using ANOVA followed by post hoc unpaired t test, unless otherwise specified. The significance of relationships between variables was assessed using linear regression. A value of PϽ0.05 was considered statistically significant. All analyses were conducted using InStat (Prism) software.
Results
Effect of BMPR2 Ligands on EC Survival
Exposure of HPAECs for 24 hours to SF medium significantly increased apoptosis ( Figure 1A and 1B, a and b) .
Addition of BMP-2 or -7 (200 ng/mL) markedly reduced the number of the cells undergoing apoptosis in response to serum withdrawal (c and d). Figure 1C presents summary data of the results of 5 experiments showing that serum withdrawal produced a significant increase in Annexin V staining in cultured HPAECs, which could be largely prevented by the addition of either BMP-2 or -7 for 24 hours. Consistent with these results, we also observed that BMP-2 protected against apoptosis induced by TNF-␣ assessed by TUNEL staining (Figure 2A and 2B) . In separate experiments, treatment with BMP-7 also significantly reduced apoptosis in response to serum deprivation from 23.85Ϯ1.20% to 1.98Ϯ0.54% (PϽ0.05). Similarly, caspase-3 activity in response to serum deprivation was significantly reduced in cells treated with both BMP-2 and -7 compared with control cells in SF conditions ( Figure  2C ). Moreover active caspase-3, assessed by the presence of cleaved 19 and 17 kDa subunits by Western blot analysis, was reduced by BMP-2 and -7 treatment compared with control cells in SF conditions, as show on representative blot ( Figure 3A ) and summary data ( Figure  3B ), again confirming that treatment with BMP-2 or -7 for 24 hours markedly reduced apoptosis. A similar protective effect in response to BMP-2 and BMP-7 was seen in human arterial endothelial cells (HAEC) (supplemental Figure I) .
Effect of Reduced BMPR2 Expression on EC Survival
To explore whether the protective effects of BMPs were indeed mediated through BMPR2 signaling, we used specific silencing siRNA to knockdown BMPR2 expression ( Figure  4 ). Forty-eight hours after transfection with siRNA, a Ͼ50% knockdown of BMPR2 protein expression relative to ␤-actin was observed by Western analysis, whereas there was no effect of the nonsilencing siRNA (data not shown). Transfection with siRNA for lamin A/C, used as positive control, resulted in the level of inhibition as described by Qiagen (data not shown). Inhibition of BMPR2 receptor expression using specific siRNA significantly increased apoptosis in HPAECs cultured in the presence of serum (Figure 5 ), confirming the important role of this pathway in mediating EC survival signaling under basal conditions.
Effect of BMPs on Endothelial Progenitor Cells
In the next series of experiments, we examined the functional significance of these findings using EPCs isolated from the circulating blood of patients with IPAH. EPCs represent an accessible source of cells that can be differentiated to an endothelial phenotype 21 and thus can provide a useful surrogate for somatic human endothelial cells. After 7 days in differential culture, EPCs exhibited a typical endothelial-like morphology ( Figure 6A, a) , and Ͼ80% of cells were positive for EC markers including Tie2, VEGFR2, and UEA-1 lectin ( Figure 6, b and d, respectively) . EPCs from patients were qualitatively similar to those from normal controls, and neither showed evidence of differentiation to myofibroblast lineage under the conditions studied (supplemental Figure II) .
There was no significant difference in basal rates of apoptosis in EPCs from patients with IPAH versus normal controls 24 hours of serum withdrawal (21.06Ϯ2.89% versus 14.58Ϯ3.05%, respectively), although there was a tendency toward slightly higher rates in IPAH cells when grown in the presence of serum (7.69Ϯ2.04% versus 3.18Ϯ0.71%, respectively). However, with the addition of BMP-2, EPCs from control subjects showed a highly significant reduction in the rate of apoptosis (Ϸ50% inhibition, Figure 6B ) consistent with a protective effect of BMP/BMPR2 signaling in a manner analogous the normal HPAECs. In contrast, the protective effect of BMP-2 was markedly altered in EPCs derived from IPAH patients compared with those isolated from normal subjects. Although some patients exhibited weak protection, the majority demonstrated a paradoxical increase in apoptosis in response to BMP-2, and overall this response was significantly different from cells derived from normal subjects (Pϭ0.02). Interestingly, the magnitude of response to BMP-2 was associated with the hemodynamic severity the PAH (PϽ0.05), such that the patients with the highest PAP exhibited the most dramatic increase in apoptosis ( Figure  6C ).
Expression of BMPR2 Receptor by Human EPCs
We assessed BMPR2 receptor expression to determine whether the heterogeneous response to BMP-2 in EPCs from patients with PAH might be attributable to varying levels of receptor expression. Cells from both control subjects and patients with PAH showed similar patterns of BMPR2 expression by immunostaining ( Figure 7A ). Moreover, there were no significant differences in mean BMPR2 mRNA levels assessed by quantitative RT-PCR between EPCs from PAH patients and controls ( Figure 7B ), although there was considerable individual variation, with some patients exhibiting reduced expression and others exhibited levels up to 2-to 3-fold higher than the mean. However, when BMPR2 mRNA expression was plotted against magnitude of apoptosis in response to BMP-2, no relationship was seen ( Figure 7C ).
Discussion
This is the first demonstration that the BMP/BMPR2 pathway protects against EC apoptosis, which is in sharp contrast to its well-established proapoptotic and growth inhibitory effects in smooth muscle cell (SMC) lines. In this report, we show that BMPs decreased apoptosis in response to serum deprivation and TNF-␣, whereas knockdown of the BMPR2 using siRNA increased the basal level of apoptosis in normal HPAECs. Moreover, defects in this pathway may be relevant clinically, because we also show altered response to BMP-2 in EPCs isolated from patients with IPAH compared with those from normal subjects. These observations may have important implications regarding the link between mutations in the BMPR2 gene and the development of disease and suggest that, in addition to dysregulated SMC growth, patients with this mutation may be more susceptible to EC loss, which has now been implicated as an initiating event in the pathogenesis of PAH in various experimental models. 4, 22 The recent identification of the association between mutations of the BMPR2 receptor and idiopathic PAH, 8, 11, 23, 24 both familial and sporadic, represents a major advance toward an understanding of the complex pathogenic mechanisms that underlie this fatal disease. Although BMPR2 is expressed by both pulmonary artery endothelial and SMCs, most investigations have focused on the potential importance of BMPR2 mutations on SMCs 25 and a clear picture has emerged that BMP signaling represents an inhibitory pathway, which prevents excessive pulmonary arterial muscularization by reducing SMC growth and increasing apoptosis. 15, 16 However, if anything BMPR2 is found to a greater extent on the pulmonary vascular endothelium than in the surrounding SMCs. 26 Moreover, lung vascular endothelium has been recently reported to exhibit high levels of activation of downstream signaling molecules (ie, SMADs), 27 further implicating the endothelial BMPR2 system in this disease. PAH has also been described in patients harboring mutations in endothelial restricted gene, the ALK-1, another member of the TGF family of receptors. 28 -30 These mutations that are well known to be associated with arteriovenous malformations that are characteristic of hereditary hemorrhagic telangiectasia (HHT). 28, 29 The fact that mutations in an endothelial-restricted gene have now been linked to IPAH further implicates the endothelium as a critical target in the molecular pathogenesis of this disease. Therefore, the elucidation of the functional importance of BMP signaling in ECs as opposed to SMCs may provide important insight into the mechanisms whereby mutations of this receptor result in predisposition for PAH.
Our results strongly suggest that BMPs protect against apoptosis in HPAECs, which support a role for the BMPR2 pathway in survival signaling in normal human pulmonary endothelium. Therefore, mutations in the BMPR2 receptor, and possibly other related pathways, may lead to increased EC loss in response to environmental triggers. Loss of microvascular endothelium, particularly at the level of the fragile precapillary arterioles, which consist of little more than endothelial tubes, could result loss of continuity of distal arterioles, thus progressively excluding portions of the microvasculature from the pulmonary circulation. 6 Indeed, we have shown that loss of precapillary arteriolar continuity precedes the development of PAH in the monocrotaline model and that gene transfer of EC survival factors such as VEGF and angiopoietin-1, prevented the development pulmonary vascular disease. 5, 6 Similarly, inhibition of VEGF signaling was reported to result in marked potentiation of PAH in the chronic hypoxic model, associated with exaggerated vascular remodeling and evidence of angioproliferative lesions. 4 Interestingly, this was completely rescued by the use of the caspase inhibitor, Z-Asp, 4, 22 again suggesting that EC apoptosis plays a central role in this model.
In this report, we also examined the effect of BMPs on survival of EPCs harvested from the circulating blood of patients with IPAH compared with normal subjects. Increasingly, it is recognized that these bone marrow-derived cells circulate postnatally in the peripheral blood and are believed to home to regions of the vasculature with injured endothelial lining, and a variety of diseases are characterized by alterations in the number or quality of circulating EPCs. [31] [32] [33] [34] The present data show that EPCs from patients with IPAH are abnormal in terms of their response to BMPs. Although the mutation status of our PAH cohort is not known, it is likely that the majority of these patients with sporadic disease would not harbor a mutation in the BMPR2 gene. 35 A Figure 6 . A, Cells were plated on fibronectin-coated slides and grown in EBM-2 MV medium for 7 days, and EPC differentiation was determined by immunohistochemistry. EPCs exhibited typical endothelial-like morphology, as shown in this phase contrast image (a). Cells were stained for the endothelial makers including Tie2 (b), VEGFR-2 (c), and UEA-1 (d) and examined by confocal microscopy. Eighty to ninety percent of cells were positive for the above markers after 7 days in culture. B, EPCs from control subjects and IPAH patients were exposed to BMP-2 (200 ng/mL, 24 hours) in SF medium, and the number of cells undergoing apoptosis was analyzed by fluorescence-activated cell sorting. C, Response to BMP-2 under SF conditions on EPCs isolated IPAH patients is shown on y-axis as percent change in apoptosis plotted against mean of pulmonary arterial pressure (mPAP) on the x-axis. *PϽ0.05 vs SF, no BMP-2; †PϽ0.05 vs normal.
reduction in the survival in response to BMP-2 is consistent with a possible downregulation of receptor expression, as has been previously reported in the pulmonary vasculature of patients with IPAH. 26 However, we saw no overall reduction in BMPR2 expression in EPCs from patients with IPAH compared with normal controls. Rather, the increase in apoptosis, which was seen in cells from the majority of patients, is consistent with abnormal signaling in response to BMPs, as was described in SMCs of patients with IPAH. 36, 37 Of note, there was a significant correlation between the degree of EPC apoptosis induced by BMP and the severity of hemodynamic abnormality in the pulmonary bed. Although this might indicate that patients exhibiting this response were predisposed to develop severe PAH, we cannot exclude a confounding effect of hemodynamic factors (ie, increased shear forces) or concomitant drug therapy (ie, epoprostenol).
Nevertheless, the present results suggest that mutations of BMPR2, and possibly related genes as well, could lead to diametrically opposite consequences in ECs and SMCs, which may both contribute importantly to the development of PAH (supplemental Figure III) . In pulmonary endothelium, loss of BMPR2 signaling may increase the susceptibility to programmed cell death in response to injurious environmental stress, particularly at the level of the distal "precapillary" arterioles. EC apoptosis could be an initiating mechanism for IPAH, leading directly to microvascular obliteration, as a result of degeneration of these fragile endothelial structures. 38 Alternatively, repeated waves of EC loss may indirectly result in a reactive increase in proliferation of the remaining endothelium and provide conditions favoring the emergence of apoptosis-resistant, hyperproliferative ECs, which is characteristic of the later stages of this disease. 39 In contrast, the same mutation in pulmonary SMCs will result in the loss of inhibitory regulation of cell growth, thus amplifying medial hypertrophy occurring in response to abnormal pulmonary hemodynamics and increased vasoconstrictor/growth factor expression (ie, serotonin and endothelin). 40 Taken together, this paradigm may help explain why the lung is uniquely susceptible to extreme vascular remodeling resulting from haploinsufficiency in a growth and differentiation receptor that is ubiquitously expressed in all tissues throughout the body. 
